Dorsal root ganglion (DRG) neurons are the primary sensory neurons that transmit somatosensory information from peripheral tissues to the spinal cord. In chronic neuropathic pain states, these neurons undergo maladaptive plasticity including sensitization, ectopic firing, and altered gene expression, transforming from faithful sensory transducers into autonomous pain generators. Understanding DRG neuron dysfunction is essential for developing targeted analgesic therapies with improved efficacy and reduced central nervous system side effects.[1][2]
DRG neuron pathology also contributes to non-motor symptoms in neurodegenerative diseases including Parkinson's disease, where peripheral sensory dysfunction precedes motor symptoms, and in amyotrophic lateral sclerosis, where altered pain processing affects quality of life.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4023189 | parasol ganglion cell of retina |
DRG neurons are pseudo-unipolar neurons with a single axon that bifurcates into:
The cell bodies reside in the DRG, a cluster of neurons in the intervertebral foramen, protected by the blood-nerve barrier (less restrictive than the blood-brain barrier).
| Property | Description |
|---|---|
| Location | Dorsal root ganglia (all spinal levels) |
| Morphology | Pseudo-unipolar |
| Diameter range | 10-100 μm (size correlates with function) |
| Myelination | Large: Aβ/Aα; Medium: Aδ; Small: Unmyelinated C |
DRG neurons are classified by function, size, and molecular markers:
| Type | Diameter | Myelin | Markers | Function |
|---|---|---|---|---|
| Nociceptors | Small | None (C) or thin (Aδ) | TRPV1, Nav1.8, CGRP | Pain detection |
| Mechanoreceptors | Large | Thick (Aβ) | TrkC, Parvalbumin | Touch, proprioception |
| Thermoreceptors | Small | None | TRPM8, TRPV3 | Temperature |
| Pruriceptors | Small | None | MrgprA3, NPPB | Itch sensation |
| Proprioceptors | Large | Thick (Aα) | Parvalbumin, TrkC | Position sense |
| Marker | Population | Function |
|---|---|---|
| Nav1.7 (SCN9A) | Nociceptors | Action potential initiation |
| Nav1.8 (SCN10A) | Nociceptors | Pain-specific Na+ current |
| Nav1.9 (SCN11A) | Nociceptors | Threshold regulation |
| TRPV1 | Peptidergic C | Heat, capsaicin receptor |
| TRPA1 | Non-peptidergic | Cold, irritant receptor |
| TRPM8 | Cold receptors | Cold sensation |
| CGRP | Peptidergic | Vasodilation, neurogenic inflammation |
| Substance P | Peptidergic | Neurogenic inflammation |
| IB4 binding | Non-peptidergic | Glial cell line-derived neurotrophic factor (GDNF) responsive[3] |
DRG neuron terminals express specialized transducer channels:
These channels convert physical/chemical stimuli into depolarizing receptor potentials, triggering action potential generation in the axon initial segment.
The unique pseudo-unipolar morphology allows "through-conduction"—action potentials bypass the soma during normal transmission, traveling directly from peripheral to central terminals. This efficiency is disrupted in neuropathic states.[4]
Following nerve injury, DRG neurons develop hyperexcitability through:
| Mechanism | Molecular Basis | Consequence |
|---|---|---|
| Na+ channel upregulation | Nav1.3, Nav1.7, Nav1.8 increased | Lower threshold, ectopic firing |
| K+ channel downregulation | KCNQ, KV reduced | Prolonged depolarization |
| Ca2+ channel changes | Cav3.2 upregulation | Burst firing, transmitter release |
| Receptor sensitization | TRPV1, TRPA1 phosphorylation | Enhanced responsiveness |
| Gene expression shifts | ATF3, c-Jun activation | Altered phenotype |
Injured DRG neurons generate spontaneous action potentials without peripheral input:
This ectopic activity creates spontaneous pain (constant burning, aching) independent of peripheral stimuli.[5]
Ectopic DRG firing drives spinal cord sensitization through:
Central sensitization amplifies all sensory input, producing allodynia (pain from non-painful stimuli) and hyperalgesia (enhanced pain from painful stimuli).
Nerve injury triggers a cascade of transcriptional changes in DRG neurons:
| Gene Class | Changes | Functional Impact |
|---|---|---|
| Sodium channels | Nav1.3 ↑, Nav1.8 ↓, Nav1.9 ↓ | Hyperexcitability |
| Potassium channels | KCNQ2/3 ↓, KV1.1/1.2 ↓ | Prolonged depolarization |
| Calcium channels | Cav3.2 ↑ | Burst firing |
| Neuropeptides | GAL ↑, NPY ↑, SP ↓, CGRP ↓ | Altered modulation |
| Neurotrophin receptors | TrkA ↓, p75 ↑, Ret ↑ | Trophic factor dependence shift |
| Inflammatory mediators | TNF-α ↑, IL-1β ↑, IL-6 ↑ | Autocrine sensitization |
| Transcription factors | ATF3 ↑, c-Jun ↑, STAT3 ↑ | Phenotype switching |
Chronic pain induces lasting epigenetic changes:
These mechanisms contribute to pain chronicity and treatment resistance.[6]
Following nerve injury, the DRG becomes infiltrated by:
These immune cells release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that directly sensitize DRG neurons.
Satellite glial cells (SGCs) envelop each DRG neuron and become activated in neuropathy:
SGC-neuron signaling creates a feed-forward sensitization loop.[7]
Peripheral sensory dysfunction is an early feature of PD:
The sensory symptoms contribute significantly to reduced quality of life and are often undertreated.[8]
Diabetic peripheral neuropathy provides insights into metabolic contributions to neurodegeneration:
| Target | Agent | Status |
|---|---|---|
| Nav1.7 | PF-05089771, CNV1014802 | Phase II failed |
| Nav1.8 | Suzetrigine (VX-548) | Phase III (FDA submission) |
| TRPV1 | Capsaicin patch (high-concentration) | Approved |
| TRPA1 | GRC 17536 | Phase II failed |
| Cav2.2 | Ziconotide (intrathecal) | Approved |
| α2δ subunits | Gabapentin, pregabalin | Approved (limited efficacy) |
Emerging strategies targeting DRG:
Woolf CJ. Pain: moving from symptom control toward mechanism-targeted management. Ann Intern Med. 2004;140(6):441-451. https://doi.org/10.7326/0003-4819-140-6-200403160-00010. 2004. ↩︎
Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11. Pain. 2019;160(1):28-37. https://doi.org/10.1097/j.pain.0000000000001390. 2019. ↩︎
Usoskin D, Furlan A, Islam S, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci. 2015;18(1):145-153. https://doi.org/10.1038/nn.3881. 2015. ↩︎
Krames ES. The dorsal root ganglion in chronic pain and as a target for neuromodulation: a review. Neuromodulation. 2015;18(1):24-32. https://doi.org/10.1111/ner.12247. 2015. ↩︎
Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res. 2009;196(1):115-128. https://doi.org/10.1007/s00221-009-1724-6. 2009. ↩︎
Denk F, McMahon SB, Tracey I. Pain vulnerability: a neurobiological perspective. Nat Neurosci. 2014;17(2):192-200. https://doi.org/10.1038/nn.3628. 2014. ↩︎
Chen G, Luo X, Qadri MY, et al. Female-specific latent sensitization of dorsal root ganglia via satellite glial cell signaling. J Neurosci. 2023;43(7):1125-1138. https://doi.org/10.1523/JNEUROSCI.1652-22.2022. 2023. ↩︎
Cury RG, Galhardoni R, Fonoff ET, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2016;20(2):151-165. https://doi.org/10.1002/ejp.724. 2016. ↩︎
Moren C, Vissienna T, Youssefian S, et al. Gene therapy for neuropathic pain: progress and prospects. Nat Rev Drug Discov. 2024;23(1):27-47. https://doi.org/10.1038/s41573-023-00813-5. 2024. ↩︎